Prostate cancer (PCa) treatment remains challenging, especially in advanced stages, where the lack of sensitivity and specificity of available biomarkers makes it difficult to establish an accurate prognosis.
To assess the safety and feasibility of extraperitoneal single-port robotic assisted laparoscopic radical prostatectomy using the da VinciⓇ SP robotic platform for same-day surgery. Extraperitoneal single-port robotic prostatectomy (ESRP) using the da VinciⓇ SP platform was performed on 60 patients with clinically localized prostate cancer and no prior definitive therapy.
The androgen receptor (AR) splice variant V7 (AR-V7) is an emerging marker to aid clinical decision-making in patients with castration-resistant prostate cancer (CRPC). A number of studies have shown that a subset of patients also express AR-V7 in the primary tumor.
To assess predictors of PSMA expression in a genomic database; positron emission tomography (PET) with PSMA-targeted radiopharmaceuticals is increasingly being utilized. The de-identified Decipher Biosciences database (GRID), which includes expression for more than 46,000 coding and noncoding genes per patient, was queried for expression of FOLH1 (PSMA).
We assessed whether D2-40/podoplanin (PDPN) could be used to identify bladder cancer patients with a higher probability of benefiting from cisplatin-based combination chemotherapy. We investigated PDPN expression by immunohistochemical analysis of cystectomy specimens from 96 bladder cancer patients who had undergone radical cystectomy without neoadjuvant or adjuvant cisplatin-based combination chemotherapy until recurrence.
To build a CT-based radiomics model to predict the pathological grade of bladder cancer (BCa) preliminarily. Patients with surgically resected and pathologically confirmed BCa and who received CT urography (CTU) in our institution from October 2014 to September 2017 were retrospectively enrolled and randomly divided into training and validation groups.
Interim data from the PURE-01 study, using pembrolizumab before radical cystectomy in muscle-invasive bladder cancer (MIBC), suggested that multiparametric magnetic resonance imaging (mpMRI) was able to predict the pathologic response.
Galectin-1 protein has been recently recognized as a valuable urinary biomarker for the diagnosis and prognosis of bladder cancer. Herein, we present a sensitive and specific impedimetric immunosensor for the quantitative and label free detection of Galectin-1 protein in clinical urine samples.
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of gastrointestinal and extraintestinal malignancies. However, the associations between IBD and prostate cancer (PCa) risk remain conflicting.Methods: We conducted a systematic literature search in PubMed, EMBASE, and Web of Science databases. According to the inclusion and exclusion criteria, a total of nine studies were […]
In the constant search for better approaches to treat and ultimately prevent prostate cancer, it is essential that we better understand the underlying etiology of prostate cancer. In times like this, I am often discouraged by the common mantra that the only known risk factors for prostate cancer are “age, race, and family history”. Surely, […]
